Natera at ISLB 2026
Nov 7–9, 2026 Madrid, Spain ~700 attendees Website
Natera brings 2 presentations to ISLB 2026 in Madrid, and exhibits at Booth 29. Its work centres on circulating tumour DNA testing for molecular residual disease and real-time disease monitoring, including the Signatera Genome assay in solid tumours. One study weighs the budget impact of tumour DNA-guided decisions after bladder removal in high-risk muscle-invasive bladder cancer in the United Kingdom.
| Organization | ISLB 2026 Attendance |
|---|---|
Natera Austin, TX | ◇Bronze Sponsor |
Offers Signatera, a personalized ctDNA test used to assess molecular residual disease and monitor treatment, validated in multiple cancer types. | Booth Exhibiting at Booth 29 Sat, Nov 710:00am–4:00pm, 6:00–7:30pmSun, Nov 810:00am–4:00pmMon, Nov 98:30am–10:30am Talk Sat Nov 7 3:15pm–4:00pm Industry Mon Nov 9 9:00am–10:00am |
Instantly find 20 buyers from Natera
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the International Society of Liquid Biopsy (ISLB). Submit a correction